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CHAPTER 1: INTRODUCTION 
 
The Human Immunodeficiency Virus 1 (HIV-1) presents a major challenge, both locally and 
globally. KwaZulu-Natal is the epicenter of the pandemic with infection rates as high as 25% in 
areas of the population (Kharsany and Karim, 2016). Whilst antiretroviral (ARV) drug treatments 
are readily available to those infected with HIV-1 and are able to successfully suppress the 
virus/suppress viremia, they are not curative (Sigal and Baltimore, 2012). It is unsustainable for 
individuals living with HIV-1 to take daily medication for the rest of their lives, especially in the 
developing world, where access to medication may be limited. Therefore, it is critical that the 
HIV-1 reservoir is identified in order to pave a way for a functional cure.  
Should an individual stop antiretroviral therapy (ART), viral levels in the plasma will rebound, 
even when their plasma viremia has been suppressed to undetectable levels for several years 
(Chun et al., 2015, Eriksson et al., 2013, Licht and Alter, 2016). This reservoir may be maintained 
by a population of latently infected cells (Siliciano and Greene, 2011), or by ongoing replication 
(Lorenzo-Redondo et al., 2016, Sigal et al., 2011). This is as a result of the HIV-1 reservoir: 
sanctuary sites throughout the body that are thought to include the central nervous system (CNS) 
(Fois and Brew, 2015, Hellmuth et al., 2015), gut (McElrath et al., 2013, Yukl et al., 2013), genital 
tract (Marcelin et al., 2008, Politch et al., 2012), and lymph nodes (Horiike et al., 2012, Spiegel 
et al., 1992) as well as latently infected T cells in the blood (Kulpa and Chomont, 2015, Svicher 
et al., 2014).  These sanctuary sites may harbor replication-competent virus (Soriano-Sarabia et 
al., 2014, Wang et al., 2018a, Wang et al., 2018b) in specific cell subsets. Identifying which cells 
harbor replication-competent virus is crucial in the eradication of the reservoir without depleting 
cells that make up a large immune system compartment.  
The latent HIV-1 reservoir persists in CD4+ T cells, where the cells are infected but not actively 
producing virus. This is established during acute infection, likely within the first days of infection 
(Chun et al., 1998, Ruelas and Greene, 2013), and is transcriptionally silent with a long half-life 
(Finzi et al., 1999, Siliciano and Greene, 2011). Research has shown that cells with single 
integrations of HIV-1 decreased over time on therapy and that the cells that remained infected 
had integrated HIV-1 in the silent regions of their genome (Cohn et al., 2015). However, latency 
reversal agents are being studied, to reactivate transcription of HIV-1 in these cells, which could 
cause the immune system to either clear the cells or for them to spontaneously die (Ruelas and 
Greene, 2013). The HIV-1 reservoir in lymph nodes presents an obstacle to the eradication of the 
infection, as it allows for the virus to persist in the presence of ART (Kulpa and Chomont, 2015, 
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Kutscher et al., 2016, Reeves et al., 2018, Lorenzo-Redondo et al., 2016). Identifying which cell 
types in the lymph node harbour competent virus is key to developing a possible cure for HIV-1 
(Chun et al., 2015, Siliciano and Siliciano, 2015, Churchill et al., 2015, Sigal et al., 2011).  
Ongoing replication is another proposed mechanism whereby HIV-1 persists in the presence of 
ART (Lorenzo-Redondo et al., 2016, Sigal et al., 2011). Due to low drug penetrance in lymphoid 
tissue, HIV-1 is able to replicate and infect new cells, including through cell-to-cell spread of the 
virus (Sigal et al., 2011). This can allow for evasion of the immune system, a further contributing 
factor to HIV-1 persistence (Sattentau, 2008). Research in support of ongoing replication found 
an increase in episomal DNA, by increasing the intensity of a suppressive ART regimen through 
the addition of raltegravir, which is an indicator of ongoing replication (Buzon et al., 2010). 
However, ongoing replication is a controversial school of thought and the model of latency is 
generally preferred. 
Several recent studies have proposed cellular locations for the HIV-1 reservoir in the face of ART. 
CD32a was identified as a marker of a potential CD4+ T cell reservoir in peripheral blood 
mononuclear cells (PBMCs) (Descours et al., 2017). When cells from ART suppressed 
individuals were assessed for infection frequency, CD32a+CD4+ T cells had a 1000-fold higher 
level of HIV-1 DNA than CD32a-CD4+ T cells (Descours et al., 2017). A quantitative viral 
outgrowth assay for inducible replication-competent provirus found a 3000-fold enrichment in 
CD32a+ cells in comparison to total CD4+ T cells (Descours et al., 2017). 
A second putative cellular HIV-1 reservoir in the T cell compartment is the programmed cell 
death protein 1 (PD-1) cell subset, which is mainly composed of T follicular helper cells (Banga 
et al., 2016, Perreau et al., 2013). Populations of these cells were found to harbour more 
replication-competent virus than other memory CD4+ T cell subsets in both blood and lymph 
nodes from ART suppressed individuals (Banga et al., 2016). PD-1 lymph node cells from 
individuals who had been on long term ART had higher levels of HIV-1 RNA present than any 
other memory CD4+ T cell subset, indicating that PD-1+ cells could be a major source of 
replication-competent provirus in both the blood and lymph nodes and a site of active viral 
replication during long term ART (Banga et al., 2016). 
The majority of research focused on the HIV-1 reservoir has been conducted in the Western 
World, using in vitro models with lab strains of HIV-1 or in vivo infected samples from 
individuals with Clade B HIV-1 (Omondi et al., 2019, Siliciano and Greene, 2011).  It is currently 
unclear what the cellular source of the HIV-1 reservoir in sub-Saharan Africa, and specifically in 
South Africa, is. Very few studies have been conducted on lymph nodes (Cohen, 2011) and none 
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in lymph nodes from individuals infected with Clade C HIV-1 from South Africa. We investigated 
the cellular source of HIV-1 in the presence of suppressive ART in lymph nodes from surgical 
resections. These samples were unique, since they allowed access to the HIV-1 reservoir in large, 
non-superficial lymph nodes, which provided a rich cellular infection environment for the virus.  
We hypothesized that the HIV-1 reservoir in the face of ART was contained in a specific T cell 
subset that could be identified by surface markers. The aims of the study were to:  
1) Assemble a cohort of lung lymph nodes from ART suppressed individuals 
2) Determine the cell subtype which could express inducible HIV-1 through large-
number/high-throughput single-cell RNA sequencing using Seq-Well technology and 
flow cytometry, including anti-HIV-1 p24 Gag staining  
3) Generate full length HIV-1 genome sequences from RNA and DNA extracted from the 
lymph node cells and functionalize these to create infectious molecular clones 
We assembled a cross-sectional cohort of study participants in collaboration with clinicians at the 
Department of Cardiothoracic Surgery at Inkosi Albert Luthuli Central Hospital in Durban, South 
Africa. We selected lymph nodes from seven HIV-1 positive study participants and three HIV-1 
negative study participants, based on their viral load, number of years on ART, and TB status 
(Table 1). Liquid chromatography-mass tandem spectrometry (LC-MS-MS) was run on the 
matched PBMCs from each study participant to detect ART levels and whether the study 
participant was adhering to their regimen (Table 2). We quantified the percentage of infection in 
the cells using anti-HIV-1 p24 Gag staining as well as staining with the J3 anti-Env broadly 
neutralizing nanobody. We found that the percentage of infected cells varied between study 
participants from 0.034% to 0.16%, indicated by p24+ cells (Figure 1). 
In collaboration with Professor Alex Shalek and his graduate student, Carly Ziegler, at the 
Massachusetts Institute of Technology, we optimized methods related to the single-cell RNA 
sequencing technology Seq-Well, that has been developed by the Shalek laboratory (Gierahn et 
al., 2017). We initially ran several pilot studies to determine whether it was possible to detect 
HIV-1 transcripts as well as the depth of detection down to single base-pair mutations. Rev-CEM-
E7 cells were infected with NL4-3, NL4-3 containing the L100I mutation, or both virus strains. 
Single cells were sorted and sequenced and the HIV-1 transcripts were detected down to the base-
pair mutation as well as the abundance of viral transcripts per cell (Figure 3). To detect the 
resolution of HIV-1 infection using the Seq-Well platform, lymph node cells from HIV-1 negative 
study participants were infected with blue fluorescent protein (BFP) tagged NL4-3 or JR-CSF 
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and BFP positive cells were sorted.  A threshold for the level of background was determined by 
comparing BFP positive cells to mock infected cells (Figure 4). 
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Seq-Well allows for the high-throughput sequencing of thousands of single cells in parallel from 
low-input samples. A pilot was run on lymph node cells from PID 024-09-0198, and HIV-1 
transcripts were detected in various T cell subsets as well as in myeloid lineage cells (Figure 6). 
However, due to the rarity of HIV-1 infected cells in the lymph node compartment from an 
individual who is suppressed on ART, we had to optimize methods to enrich for HIV-1 infected 
cells. We optimized the anti-Env broadly neutralizing camelid nanobody J3 (McCoy et al., 2012) 
to select for HIV-1 infected cells, firstly using flow cytometry and then using magnetic-activated 
cell sorting columns (MACS), before loading the J3 positive cells onto Seq-Well arrays (Figure 
2 & 7). The MACS columns were also used to enrich for CD4+ T cells, as these were most likely 
the cells that would harbor HIV-1, and to deplete CD19+ B cells, as these made up a large portion 
of the cells found in the lymph nodes. We loaded seven arrays in total per study participant, both 
HIV-1 negative and HIV-1 positive: two unsorted, two CD4+ enriched, two CD19+ depleted, and 
one J3+ enriched. We found HIV-1 transcripts in T cell and myeloid lineage cell types (Figure 7).  
To validate the infected cell types, flow cytometry was run on the lymph node cells from PID 
024-09-0276, using anti-HIV-1 p24 Gag and anti-Env J3 in combination with cell type markers 
for major cell lineages. We found cells doubly positive for p24 in CD3+CD4+ T cells as well as 
in CD33+ myeloid cells. We looked further into different myeloid lineage cells, including CD14+ 
cells and CD68+ cells and found cells positive for both p24 and J3. Further characterization of the 
T cell subsets is still needed (Figure 7). 
In conjunction to the single-cell RNA-sequencing, full length genomes were cloned from the 
lymph node cells using extracted DNA and RNA. The genomes were cloned in two parts, 
sequenced, and then combined to form HIV-1 genomes specific to each study participant. The 
single-cell RNA-sequencing data from each study participant was aligned to the genome from the 
same study participant as well as to the HIV-1 Clade C consensus sequence. This was done in 
collaboration with Dr. Alejandro Balazs, and his post-doctoral fellow Dr. Martin Deymier, at the 
Ragon Institute of MGH, MIT and Harvard (Figure 5) 
Using a variety of techniques optimized to specifically identify HIV-1 infected cells, in lymph 
nodes from ART suppressed individuals, allowed us to identify the infected cells and build on the 
research that exists in this field. Further characterization of the exact T cell subsets is still required 
however, the existing data presents T cells and myeloid lineage cells as being the main infected 
cell types in the presence of ART. Understanding how the reservoir presents itself in these 
individuals is critical for creating a functional cure that could reduce or eradicate the HIV-1 
reservoir. This would allow individuals infected with HIV-1 to be in a state of monitored 
remission in future studies
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CHAPTER 2: IDENTIFYING THE CELLULAR HIV-1 RESERVOIR IN 
LYMPH NODES OF ANTIRETROVIRAL THERAPY SUPPRESSED 
INDIVIDUALS 
 
Abstract 
HIV-1 infection is suppressed but not cured in the face of antiretroviral therapy (ART). 
Pinpointing the cellular HIV-1 reservoir, which allows HIV-1 to persist, is key to the eradication 
of the virus. Lymph nodes are known to be a reservoir site for HIV-1 persistence, and we have 
assembled lymph nodes from a cross-sectional cohort of participants on suppressive ART to better 
understand the cellular HIV-1 reservoir. We developed a novel single-cell RNA-Seq 
methodology to identify the cellular HIV-1 reservoir in the lymph node compartment in ART 
suppressed individuals. HIV-1 positive cells from these lymph nodes were stained with anti-HIV-
1 antibodies and selected using flow cytometric sorting. Seq-Well, a high throughput single-cell 
RNA-Seq approach, was then performed to detect gag and env HIV-1 transcripts in individual 
cells, as well as the infected subtype using the cellular transcriptome. In parallel, the consensus 
near full length viral clone from the lymph node was sequenced and used for alignment. Using 
our methods for identifying HIV-1 infected cells from lymph nodes from chronically infected 
individuals, we have identified both known and novel putative host markers that are associated 
with persistent infection. These included co-expression of APOBEC3G, NFAT5, and NFKB2 in 
cells that contained HIV-1 mRNA. Our results show that cells with transcriptomes consistent with 
a T cell origin are the main infected population, and we are in the process of deeply characterizing 
the cell subtypes involved that also express markers of HIV-1 infection.  
Introduction 
HIV-1 presents a major global public health burden, particularly in sub-Saharan Africa. South 
Africa, and in particular the province of KwaZulu-Natal, is one of the epicentres of the HIV-1 
pandemic (Kharsany and Karim, 2016). Most individuals who take antiretroviral therapy (ART) 
are not viraemic but lifelong suppression is challenging, both economically and logistically. There 
are multiple mechanisms whereby HIV-1 infection may persist in the presence of ART. These 
include latency versus ongoing replication which can occur in several reservoir sites throughout 
the body including the lymph nodes, gut, brain, and genital tract (Fois and Brew, 2015, Horiike 
et al., 2012, Kulpa and Chomont, 2015, McElrath et al., 2013, Svicher et al., 2014). 
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In recent years, varying cell types including T follicular helper cells, programmed cell death 1 
(PD-1) cells, and T cells expressing CD32a (Descours et al., 2017), have been described as the 
cellular HIV-1 reservoir (Banga et al., 2016, Noto et al., 2018, Fromentin et al., 2016). Cell types 
such as central memory T cells have been found to be preferentially infected over other T cell 
subsets, such as effector memory T cells and transitional memory T cells (Fromentin et al., 2019). 
These cell types have been shown to harbour replication-competent virus (Lee and Lichterfeld, 
2016, Siliciano and Siliciano, 2015). 
 
It has also been reported that macrophages are able to be infected by HIV-1 and lead to the 
persistence of the HIV-1 reservoir. T cells maintain the HIV-1 reservoir through homeostatic 
proliferation of latent T cells, (Chomont et al., 2009) whereas macrophages are long-lived and 
have been shown to be resistant to the cytopathic effects of HIV-1 replication in in vitro studies 
(Castellano et al., 2017, Clayton et al., 2018). Macrophages have also been shown to be infected 
in vivo and form HIV-1 reservoirs in an in vivo mouse model (Honeycutt et al., 2016, Mlcochova 
et al., 2014) as well as in humans (Castellano et al., 2017). The primary cell types infected by 
HIV-1 in the brain are myeloid lineage cells such as microglia or perivascular macrophages 
(Gorry et al., 2001, Schnell et al., 2009, Schnell et al., 2011, Williams et al., 2001), and in some 
patients HIV-1 replication persists in the brain in the face of ART (Kugathasan et al., 2017). 
 
There are several ways in which the HIV-1 reservoir is typically measured and characterised. 
These include measuring total proviral HIV-1 DNA through qPCR and digital droplet PCR 
(ddPCR). qPCR has traditionally been used to measure proviral HIV-1 DNA, with a limit of 
detection of 50 proviral copies of DNA per CD4+ T cell (Kabamba-Mukadi et al., 2005). ddPCR 
has an advantage over qPCR, as it is able to quantitatively and discreetly measure the number of 
HIV-1 integrations, by measuring the actual amount of target DNA. Each molecule is contained 
in one droplet, which fluoresces if the droplet contains the molecule of interest. This allows for 
measurement of the initial template DNA (Rutsaert et al., 2018, Strain et al., 2013, Trypsteen et 
al., 2016). Alu-PCR is used to measure integrated HIV-1 DNA by using a non-kinetic 
preamplification step that uses primers to bind genomic Alu elements and HIV-1 gag sequences 
followed by a kinetic PCR which quantitates HIV-1 long terminal repeats (Liszewski et al., 2009, 
O'Doherty et al., 2002). The quantitative viral outgrowth assay (qVOA) is often described as the 
gold standard in terms of measuring replication-competent virus (Bruner et al., 2015). Typically, 
CD4+ T cells are isolated from blood using a negative selection method. The cells are plated in 
limiting dilution, to allow for quantification, and stimulated with phytohemagglutinin (PHA) and 
irradiated, allogeneic PBMCs from a non-infected donor. CD8+ T cells are depleted from the 
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PBMCs so as not to suppress viral replication. After several weeks replication competent HIV-1 
is detected by ELISA for the HIV-1 p24 antigen (Barton and Palmer, 2016, Siliciano and 
Siliciano, 2015). 
 
We have developed a new method approach whereby cells harbouring replication-competent 
virus across a reservoir site can be characterized. This utilizes single-cell RNA-Seq (Bradley et 
al., 2018, Rato et al., 2017), in particular the Seq-Well method (Gierahn et al., 2017). Seq-Well 
is a high throughput and easily portable method where many cells can be sequenced in parallel 
from low input samples. Here we apply this method to lymph node cells from ART suppressed 
individuals to identify various subsets of cells that are infected with HIV-1. We used the anti-Env 
broadly neutralizing nanobody J3 (McCoy et al., 2012, McCoy et al., 2014) to enrich for HIV-1 
infected cells using magnetic beads. Our data shows that there is diversity in the cell types that 
harbour HIV-1 transcripts in the lymph node cells from ART suppressed individuals. CD4+ T 
cells and macrophages make up the majority of cells that contain these transcripts, with different 
subsets of T cells containing transcripts including memory T cells and circulating T cells. This 
goes against the hypothesis that the HIV-1 reservoir is restricted to a particular cellular subset or 
can be identified with a singular cell marker.  
Results 
Quantifying HIV-1 infection in lymph node cells 
In order to quantify the size of the cellular HIV-1 reservoir in lymph nodes from ART suppressed 
study participants, a cross-sectional cohort was established in collaboration with clinicians at the 
Department of Cardiothoracic Surgery at Inkosi Albert Luthuli Central Hospital in Durban, South 
Africa. We selected lymph nodes from seven HIV-1 positive study participant and three HIV-1 
negative study participants based on their viral load, number of years on ART, and TB status 
(Table 1). Liquid chromatography-mass tandem spectrometry (LC-MS-MS) was run on the 
matched PBMCs from each study participant to detect ART levels and whether the study 
participant was adhering to their regimen (Table 2).   
Lymph node cells were fixed and stained with anti-HIV-1 p24 Gag antibody to quantify the 
number of HIV-1 infected cells. This was done for each study participant. The percentage of p24+ 
cells varied between study participants with a range between 0.034% and 0.16% (Figure 1A). We 
also determined the percentage of cells expressing Env by staining with the anti-Env broadly 
neutralizing antibodies 10-1074 and J3 and found the percentage of anti-Env positive cells to be 
slightly higher than those expressing anti-HIV-1 p24 Gag. This slight difference could be the 
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result of background staining of the J3 nanobody (Figure 1B). We optimized anti-Env antibody 
detection of infected cells using in vitro infected CD4+ T cells that were infected with 89.6, a dual 
tropic virus. CD4+ T cells were either infected with the original strain or a blue fluorescent protein 
(BFP) strain. The cells were stained with anti-HIV-1 p24 Gag and anti-Env J3 and fluorescence 
of J3 versus BFP measured and p24 versus J3 (Figure 1C). Env expression on the cell surface of 
cells infected with BFP-tagged virus was found to be decreased compared to cells infected with 
non-BFP tagged virus. This could be as a result of the BFP gene causing a disruption of 
transcription and therefore attenuating Env expression. 
 
 
Figure 1. Quantifying HIV-1 infection in lymph node cells. (A) Anti-HIV-1 p24 Gag staining 
of lymph node cells from HIV-1 positive study participants to quantify the size of the HIV-1 
reservoir in each individual. (B) Anti-HIV-1 p24 Gag staining of lymph node cells from PID 024-
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09-0276 compared with staining using the broadly neutralizing anti-Env antibodies 10-1074 and 
J3. (C) Macrophages infected with either 89.6 or BFP tagged 89.6 compared to uninfected 
macrophages in terms of BFP fluorescence or anti-HIV-1 p24 Gag staining versus anti-Env J3 
staining. 
 
Optimization of anti-Env J3  
The anti-Env nanobody J3 has typically been used as a broadly neutralizing antibody. Here, we 
optimized it for cellular staining with applications for both flow cytometry and magnetic-activated 
cell sorting (MACS) to select for HIV-1 infected cells. In vitro infected lymph node cells 
expressing surface HIV-1 envelope protein were stained with the anti-Env broadly neutralizing 
antibodies 10-1074 and J3, that were conjugated to fluorophores. The cells were infected with 
NL4-3 with a BFP tag. Enrichment was observed in comparison to staining of PBMC cells from 
an HIV-1 negative study participant when cells were acquired (Figure 2A). To verify that the anti-
Env antibodies were selecting for HIV-1 infected cells, we sorted both the negative and positive 
fractions from the HIV-1 infected cells and the HIV-1 negative cells as a true negative control. A 
nested PCR was run on the cDNA from these cells to amplify a ~200bp region of the HIV-1 
reverse transcriptase gene and gel electrophoresis to visualize the results. We found that the 
combination of J3 and 10-1074 enriched for HIV-1 infected cells. We also sorted BFP+ and BFP- 
cells to serve as controls (Figure 2B). 
We then tested the staining on lymph node cells from the in vivo infected study participant PID 
024-09-0276 (Figure 2C). We found that the combination of 10-1074 and J3 enriched for HIV-1 
infected cells. However, we found that the population of cells, when sorted, was very fragile and 
that the data generated by running Seq-Well on these cells was of low quality. Therefore, due to 
cell loss we optimized staining with J3 for magnetic-activated cell sorting using a biotinylated 
version of the J3 nanobody and enriched for HIV-1 infected cells. We ran Seq-Well on the 
enriched fraction of cells.  
We compared the number of unique molecular identifiers (UMIs), which are short sequences that 
are added to next generation sequencing libraries to identify and quantify mRNA, across all the 
samples that were sequenced and found comparable depth between them indicating sufficient 
sequencing. However, the total number of cells that were sequenced across all samples was 
variable and sample dependent. We then compared the number of UMIs between the J3 enriched 
fractions from each sample and found variability, which could be a direct result of the number of 
HIV-1 infected cells that were expressing Env on their surfaces as well as non-specific binding 
of uninfected cells to the J3 magnetic beads. The cell count from the J3 enriched fractions varied 
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greatly across the samples. The HIV-1 negative samples had some background indicating the 
level of non-specific binding that occurs. However, one sample which was antibody enriched for 
HIV-1 infected cells (PID 024-06-0312) had fewer cells with HIV-1 transcripts than the HIV-1 
negative sample. This could be due to poor quality of the cells recovered rather than the lack of 
HIV-1 infected cells (Figure 2D). The t-distributed stochastic neighbor embedding (t-SNE) plot, 
colored by PID, showing the clustering of cells from the J3 enriched Seq-Well arrays (Figure 2E).  
 
 
Figure 2. Optimization of anti-Env J3 detecting HIV-1 infected cells. (A) Enrichment of HIV-
1 infection in lymph node cells, from PID 024-09-0274, infected with BFP-tagged NL4-3 and 
stained with anti-Env J3 and 10-1074. Cell populations were sorted (1000 cells per population), 
total RNA was extracted, and cDNA synthesized. (B)  Gel electrophoresis of nested PCR 
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amplicons from the HIV-1 reverse transcriptase region (~200bp fragment) amplified from each 
sorted population. (C) Enrichment of HIV-1 infection in HIV-1 infected lymph nodes from PID 
024-09-0276 using anti-Env 10-1074 and J3 and uninfected PBMCs as a negative control. (D) 
Violin plots of the number of UMIs compared between all samples as well as the number of UMIs 
per J3 enriched array across all samples. In parallel the number of cells between all samples and 
for the J3 enriched arrays was compared. (E) t-SNE plot of the cells from the J3 enriched arrays 
colored by study participant. 
 
Single cell RNA-sequencing of in vitro infected cells to identify HIV-1 infected cells 
The HIV-1 reservoir resides in tissues niche such as the lymph nodes, where it is able to persist 
in the presence of ART. Both intrinsic drivers, such as ongoing transcription of HIV-1 within 
cells, and extrinsic drivers, such as cell-to-cell spread, allow for the persistence of the virus 
(Figure 3A). Identifying gene signatures that indicate whether a cell is infected with HIV-1 or not 
is critical to determining in vivo what cells harbor HIV-1. We used in vitro infected Rev-CEM-
E7 cells expressing GFP upon infection (Boulle et al., 2016). Cells were infected with wild-type 
NL4-3 virus, NL4-3 virus with the L100I drug resistant mutation, or a combination of both of 
these viruses. The cells from each infection were single-cell sorted into 96-well plates and single-
cell RNA-sequencing run on the cells. Each cell expressed HIV-1 as indicated by GFP 
fluorescence (Figure 3B).  
Upon sequencing of the single cells, we looked at the reverse transcriptase region of the genome 
where drug resistant mutations, such as L100I, occur. We were able to use HIV-1 transcripts 
sequenced by single-cell RNA-Seq to differentiate between the cells infected with wild type NL4-
3, those infected with the NL4-3 L100I mutant, and those infected with a combination of both 
(Figure 3C and D). Analysis of the single-cell data comparing gene expression between GFP 
positive and GFP negative cells indicated distinct gene signatures between HIV-1 positive and 
negative cells (Figure 3E). This differential gene expression correlated with the abundance of 
HIV-1 infection in each cell. An example of two genes that play a role in HIV-1 infection that 
were looked at in terms of their expression were macrophage migration inhibitory factor (MIF) 
and myxovirus resistance-2 (MX2) (Figure 3F). MIF has been shown to be found at increased 
levels in the plasma from HIV-1 infected individuals and HIV-1 infected cells release a larger 
amount of MIF than uninfected cells (Regis et al., 2010). Our single-cell RNA-Seq data shows 
that MIF expression is increased in HIV-1 infected cells and therefore was used as a gene 
signature of HIV-1 infection. MX2 has been found to inhibit HIV-1 infection post entry and was 
also tagged as a gene signature of HIV-1 infection due to its low expression in the HIV-1 infected 
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cells, indicating that the virus may have been able to override the inhibition mechanism (Goujon 
et al., 2013) (Figure 3E). 
 
 
Figure 3: Proof of concept in in vitro infected Rev-CEM-E7s. (A) Schematic of the lymph 
node as the HIV-1 reservoir and what the drivers of reservoir persistence are. (B) Rev-CEM-E7 
cells were infected with NL4-3, NL4-3 with the L100I drug resistant mutation, or a dual infection 
of both viruses. GFP cells were single cell sorted into plates. (C) The sequencing depth was able 
to recover the virus type and indicated that the depth was sufficient for detecting HIV-1 
transcripts. (D) Number of reads per cell of the reserve transcriptase region of the HIV-1 genome 
indicating sufficient reads to identify HIV-1 infection. (E) Variance in genes that were correlated 
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with HIV-1 infection. (F) MIF and MX2 are two genes that are commonly associated with HIV-
1 infection. 
Detection of HIV-1 infection from in vitro infected HIV-1 negative lymph node cells using 
single-cell RNA-Seq 
To optimize detection of HIV-1 transcripts from in vivo infected lymph node cells, we first 
optimized Seq-Well on in vitro infected lymph node cells from the HIV-1 negative study 
participants. The cells were stimulated with anti-CD3 and anti-CD28 antibodies for 5 days before 
spin infection with BFP tagged NL4-3 or BFP tagged JR-CSF. The cells were infected for 48 
hours (Figure 4A). We validated the level of infection by measuring the number of p24+ cells 
using anti-HIV-1 p24 Gag staining before sorting the BFP positive and negative fractions for both 
infections as well as the mock infected cells. We also saved an unsorted fraction of cells from 
each infection as well as the mock infected, for any downstream experiments that could be 
required for validation. Seq-Well was run on all of the conditions (Figure 4B). The transcripts 
were aligned to the Clade C consensus sequence and a cut-off determined by the number of 
transcripts from the mock infected lymph node cells that aligned to the sequence, to reduce the 
number of non-HIV-1 transcripts in the human genome with similarity to HIV-1 aligning to HIV-
1. We obtained a clear population of cells with UMIs aligning to HIV-1 in the infected conditions 
(Figure 4C).  
The UMIs that aligned to the Clade C consensus were log-normalized and 70% of BFP positive 
NL4-3 infected cells contained transcripts that aligned to the Clade C consensus sequence (Figure 
4D). We then compared percentage of HIV-1 transcripts per condition with the percentage of anti-
HIV-1 p24 Gag positive cells in each condition and found a 0.99 correlation (Figure 4E). 
Clustering of conditions by t-SNE showed clear clustering of sorted NL4-3 infected BFP positive 
cells compared with mock, NL4-3 negative cells, and sorted NL4-3 infected BFP negative cells 
(Figure 4F). Due to the percentage of infection by BFP (5.41%), the frequency of uninfected cells 
in the unsorted NL4-3 infected cells would be relatively high and therefore a likely reason as to 
these cells clustering more with the mock infected and NL4-3 infected BFP negative cells. 
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Figure 4: Resolution of HIV-1 infection from in vitro infected HIV-1 negative lymph node 
cells. (A) HIV-1 negative lymph node cells were stimulated with CD3 & CD28 antibodies for two 
days and spin infected with BFP NL4-3 or BFP JR-CSF. The infection was run for five days and 
validated with anti-HIV-1 p24 Gag staining. (B) BFP positive and negative fractions were sorted. 
Sorted and unsorted cells were loaded onto arrays for Seq-Well processing. (C & D) Resolution 
of HIV-1 alignment in infected cells compared to mock infected cells. (E) Correlation of HIV-1 
infected cells recovered from Seq-Well compared to those recovered from flow cytometry based 
on p24 staining across all conditions (unsorted: mock, NL4-3 positive, JR-CSF positive; sorted: 
BFP NL4-3 positive, BFP NL4-3 negative, BFP JR-CSF positive, BFP JR-CSF negative). (F) t-
SNE plot of each NL4-3 infection condition coloured by condition.  
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Amplification of HIV-1 virus from lymph node cells 
To improve alignment of single cell RNA-sequencing data for HIV-1 reads for each study 
participant we cloned full length HIV-1 virus from the lymph node cells (Figure 5A). This was 
done by amplifying the genome in two parts, excluding the long terminal repeat (LTR) regions, 
from RNA and DNA that were extracted from the lymph node cells. We used the Phusion High-
Fidelity DNA Polymerase (NEB) as opposed to previous methods (Deymier et al., 2014) that used 
Q-5 Hot-Start Polymerase as we found that the Phusion enzyme was better able to amplify HIV-
1 from lymph node cells than Q-5, which was optimized for amplification from plasma. We were 
able to successfully amplify HIV-1 sequences from each study participant and combine the first 
and second half genome amplicons to form one genome which was then deep sequenced (Figure 
5B). Each HIV-1 genome was used during alignment of the Seq-Well data generated from each 
lymph node. This improved alignment as opposed to aligning to the consensus HIV-1 Clade C 
genome (Figure 7D). We created a phylogenetic tree using each amplified HIV-1 genome in 
relation to the Clade C consensus sequence and NL4-3 using the neighbour-joining alignment 
type (Figure 5C). This was to ensure that there was no NL4-3 contamination as well as to look at 
the difference between each HIV-1 genome in relation to the Clade C consensus sequence, created 
from HIV-1 genomes amplified from study participants around Durban, South Africa.  
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Figure 5: Amplification of HIV-1 virus from lymph node cells. (A) Lymph nodes were 
cellularized and total RNA and DNA extracted. cDNA was synthesized from the RNA and both 
DNA and cDNA underwent a nested PCR. To amplify the HIV-1 genome from lymph node cells, 
primers were designed for the first half and second half of the genome, therefore amplifying it in 
two parts. (B) Consensus sequences from the amplified HIV-1 genomes. Several amplicons were 
sequenced and aligned for some of the PIDs, indicated by the grey bars. The black lines within 
the grey bars indicate areas of alignment. (C) Phylogeny of the amplified genomes compared to 
the consensus HIV-1 Clade C genome and NL4-3. 
 
Enrichment of cells most likely to harbor HIV-1 
We found that using flow cytometry to sort cell populations for downstream use in Seq-Well was 
causing us to lose the population of cells most likely to harbour HIV-1 and possibly be the HIV-
1 cellular reservoir in lymph nodes. Therefore, we used magnetic-activated cell sorting to enrich 
for CD4+ cells, deplete CD19+ cells, and enrich for HIV-1 infected cells using the anti-Env J3 
nanobody (Figure 7). This also eliminated the majority of dead cells as determined by cell 
counting with Trypan Blue (ThermoFisher) pre and post magnetic sorting. 
 
Cell phenotyping and identifying HIV-1 infected cells 
We chose Seq-Well as the single-cell platform to run RNA sequencing on our lymph node cells 
as it is ideal for low abundance samples and many cells can be sequenced in parallel. We initially 
ran a pilot experiment with lymph node cells from PID 024-09-0198. Cells were loaded onto 
arrays, as mentioned above, and sequenced (Figure 6A). The analysis of the Seq-Well data 
showed different cell populations that are known to be found in lymph nodes including several 
different subtypes of T cells including memory-like T cells and activated T cells. Populations of 
macrophages and antigen presenting dendritic cells were observed as well as a substantial B cell 
population, as expected (Figure 6B). Using complete gene lists generated from the t-SNE analysis 
of the single-cell data, we were able to identify various lymphocytes typically found in the lymph 
node environment (Figure 6C) and the relative contribution of these cell types to the total number 
of cells and genes recovered from the single-cell data. The major cell types identified were 
highlighted with hallmark expressed genes such as TNFRSF4 in antigen presenting cells, PAX5 
and BANK1 in B cells, and MAL and NKG7 for T cells (Figure 6D). Transcripts generated from 
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the single-cell data were also aligned to the HIV-1 Clade C consensus sequence so that we could 
identify which cells were infected (Figure 7D). 
 
 
Figure 6: Cell phenotyping and identifying HIV-1 infected cells. (A) Schematic of workflow 
from lymph node to transcriptome. (B) t-SNE of cells from PID 024-09-0198 clustered and 
colored by cell type. (C) Heatmap of top 50 genes per identified cell cluster. (D) Highly expressed 
genes per cell type allowing for the identification of cell types. (E) Number of genes in HIV-1 
negative compared with HIV-1 positive cells. We then compared the number of gag-pol 
transcripts in the HIV-1 negative cells to those in the HIV-1 positive cells to establish a threshold 
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for identifying truly HIV-1 infected cells as false positives may arise as a result of redundancy in 
the human genome. (F) We replotted the t-SNE from (B) and marked the cells that had HIV-1 
transcripts using stars. 
Total gene count between the HIV-1 negative cells and HIV-1 positive cells varied, with HIV-1 
positive cells having a higher log10 normalized gene count. However, log10 normalization reads 
mapped to the gag-pol gene between HIV-1 positive and HIV-1 negative cells indicated a high 
gene count in the HIV-1 positive cells and the complete absence of gag-pol in the HIV-1 negative 
cells (Figure 6E). We were able to plot these cells in relation to the uninfected cell subtypes on a 
t-SNE plot (Figure 6F). This gave us an indication of where to the HIV-1 cellular reservoir in 
lymph nodes may be. 
We then ran the optimized enrichment method for HIV-1 infected cells on the lymph node cells 
from six HIV-1 positive study participants and three HIV-1 negative study participants. A total 
of 22,114 cells were recovered from the Seq-Well data with 39,385 unique genes expressed 
(Figure 7A). The large number of genes recovered is as a result of alternative splicing. The lymph 
node cells that were enriched for HIV-1 infection using the anti-Env J3 magnetic column all 
clustered together from each lymph node (Figure 7B). Amongst the cell types that had transcripts 
that included the env and gag-pol genes were macrophages and CD4+ T cells. The exact subsets 
of CD4+ T cells are yet to be determined through further data analysis (Figure 7C).  
 
Flow cytometric validation of HIV-1 infected cell types  
To validate cell types that indicated the presence of viral transcripts in the transcriptomic data 
generated, we performed flow cytometry on lymph node cells from PID 024-09-0276 and 
included markers of HIV-1 infection including the anti-HIV-1 p24 Gag intracellular stain as well 
as the anti-Env broadly neutralizing antibodies 10-1074 and J3. We initially looked at the overall 
size of the reservoir as determined by these stains and the overlap between p24 positive cells and 
cells positive for the anti-Env antibodies. p24 positive cells constituted 0.069% of total cells, and 
cells doubly positive for anti-Env J3 and anti-HIV-1 p24 Gag constituted 0.052% of the total 
number of cells (Figure 7E). These frequencies were consistent with previously reported 
frequencies of HIV-1 infected cells in rectal biopsies in the face of ART as determined by HIV-
1 DNA copies (Bruner et al., 2015, Bruner et al., 2019, Eriksson et al., 2013, Omondi et al., 2019). 
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Figure 7: Identification of HIV-1 infected cells in the context of the HIV-1 reservoir in 
lymph nodes. (A) Our optimized Seq-Well workflow lead to a t-SNE plot displaying 22,114 cells 
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across all study participants (excluding PID 024-09-0219, as this had yet to be sequenced at the 
time of analysis). (B) The total number of cells coloured by experimental condition, with a defined 
J3 enriched population. (C) Cells clustered and coloured by cell type. (D) Increased alignment of 
J3 enriched single cells to the HIV-1 genome from PID 024-09-0276 than to the Clade C 
consensus sequence. (E-H) Flow cytometry validation of infected cell types using anti-HIV-1 p24 
Gag and anti-Env J3. 
We then looked at the difference in p24 and J3 double positive cells in the main cell lineages 
found in lymph nodes including CD19+ cells, CD3+ cells, and CD33+ cells (Figure 7F). As to be 
expected, we found only background levels of p24 or J3 positive cells in the CD19+ cell 
population. However, 0.27% of CD3+ cells and 43.5% of CD33+ (Mehraj et al., 2014, Rodrigues 
et al., 2017) cells were positive for both p24 and J3. T cells and myeloid lineage cells, such as 
macrophages, have been shown to form part of the HIV-1 reservoir (Castellano et al., 2017, 
Siliciano and Siliciano, 2015). Given the percentage of p24 and J3 positive cells in the CD3+ T 
cell population, we identified infected cells within the CD3+ population by gating out CD8+ cells 
and examining CD3+CD4+ T cells (Figure 7G). We found that 0.46% of these cells were double 
positives. This indicates a significant CD4+ T cell reservoir in the lymph node compartment. We 
note that while we have not tested transmission of HIV-1 from these cells, we observed both Gag 
and Env proteins, indicating the virus is functional. 
The myeloid lineage cells showed a substantial fraction of HIV-1 infection (43.5%) by the CD33 
marker. As the transcriptomic data also indicated HIV-1 infection in myeloid subsets, we looked 
further into different populations of myeloid cells, including CD14+ cells, CD68+ cells, and 
CD163+ myeloid linage cells (Figure 7H). These populations of cells were rare (0.043 to 1.91% 
of total lymphocytes). We found that 4.46% of CD14+ cells, 0.71% of CD68+ cells, and 23.1% of 
CD163+ cells were doubly positive for p24 and J3.  
 
Discussion 
Identifying the HIV-1 reservoir in the lymph node compartment from ART suppressed 
individuals required developing various assays to enrich for HIV-1 infected cells (Figure 1A). 
Previous research has identified cells expressing markers such as CD32a (Descours et al., 2017) 
and PD-1 (Banga et al., 2016) as composing the cellular HIV-1 reservoir. However, we 
hypothesized that the HIV-1 reservoir may also be present in other cell subsets or differ between 
individuals.  We therefore we chose to employ the Seq-Well method of single-cell RNA 
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sequencing, which is unbiased in terms of selecting for cell types, to identify infected cell 
subtypes. 
We assembled a cross-sectional cohort of lymph nodes from study participants, who were fully 
suppressed on ART (viral load of <40 viral copies per ml), except for PID 024-06-0338 who had 
a viral load of 58 viral copies per ml. We quantified ART regimen by LC/MS/MS and all 
individuals were in range for EFV/TFV/FTC or LPV/r/3TC suppression (Shen et al., 2008), 
except for PID 024-06-0312 who was below level of detection for TFV and had low levels of 
FTC. We initially quantified the size of the HIV-1 reservoir in the lymph node cells from each 
ART suppressed study participant by anti-HIV-1 p24 Gag staining and through the two anti-Env 
broadly neutralizing antibodies 10-1074 and J3. We established that the number of infected cells 
was less than 1% and therefore needed to be enriched for should we want to accurately identify 
the cellular subsets compromising the HIV-1 reservoir (Figure 1).  
A common marker of HIV-1 infection used during flow cytometry is anti-HIV-1 p24 Gag. 
However, as this involves paraformaldehyde fixing, it rapidly degrades the fragile RNA, and 
when de-crosslinked, very little RNA is recovered and the most fragile cells that are most likely 
infected with HIV-1, are lost. An alternative approach was to use the anti-Env broadly 
neutralizing nanobody J3 which we optimized in conjunction with the anti-Env broadly 
neutralizing nanobody 10-1074 (Caskey et al., 2017). Optimization of the anti-Env broadly 
neutralizing nanobody J3 for flow cytometry allowed us to enrich for HIV-1 positive cells when 
these cells were sorted and Seq-Well performed. However, we found that sensitive populations 
of cells were being lost in comparison to unsorted cells and therefore chose to optimize J3 
enrichment using magnetic activated cell sorting. We optimized this through in vitro infections 
of lymph node cells with BFP-tagged NL4-3 and BFP-tagged JR-CSF virus and this yielded HIV-
1 infected cells as quantified through PCR amplification of the reverse transcriptase region of the 
cells.  
Before using in vivo infected lymph node samples, we performed a proof of concept experiment, 
to determine whether we could sequence single cells to sufficient depth to identify HIV-1 
transcripts. Using two strains of NL4-3 virus, one with a drug resistant L100I mutation in the 
reverse transcriptase region, we infected Rev-CEM cells and were able to determine the virus 
with which each single cell was infected based on the presence or lack of the L100I mutation 
(Figure 3). We were also able to show gene expression in cells that correlated with HIV-1 
infection and expression that negatively correlated with HIV-1 infection. Recent studies have 
shown this in a similar model (Bradley et al., 2018, Cohn et al., 2018), where they were able to 
 23 
look at the regulation of HIV-1 transcription in infected CD4+ T cells or reconstruct the viral 
sequence in each cell from the single-cell RNA sequencing data. 
Once we were able to identify viral transcripts in single cells, we optimized our Seq-Well protocol 
with in vitro infected HIV-1 negative lymph node cells. We used a BFP fluorescent NL4-3 virus 
and BFP positive and negative cells as well as mock infected cells. Due to redundancy in the 
human genome, the short reads generated from Seq-Well may non-specifically align to the HIV-
1 genome. This experiment allowed us to determine a cut-off based on comparing the number of 
mock infected cells that aligned to the HIV-1 genome in comparison to the number of BFP 
positive cells that aligned.  
To improve HIV-1 alignment of Seq-Well reads, we successfully cloned full-length genomes 
from the lymph node cells from each HIV-1 positive study participant. We aligned the single-cell 
RNA sequencing data to both the HIV-1 Clade C consensus sequence and the cloned HIV-1 
genome.  
The pilot experiment on HIV-1 infected lymph node cells from PID 024-09-0198 indicated that 
various T cell subsets such as activated T cells, cycling T cells, and memory T cells, as well as 
antigen presenting cells (Figure 6), were infected with HIV-1. Previous research has shown some 
of these cell types to harbour the latent HIV-1 reservoir such as memory T cells (Chomont et al., 
2009, Murray et al., 2016) and activated T cells (Murray et al., 2014). Macrophages have also 
been shown to form part of the HIV-1 reservoir (Baxter et al., 2014, Castellano et al., 2017). This 
indicates that they HIV-1 cellular reservoir in lymph nodes may not be specific to a singular cell 
type or cellular marker. 
Our optimized protocol, which we ran on eight lymph node samples (two HIV-1 negative and six 
HIV-1 positive), yielded 22,14 cells and recovered 39,385 unique genes. We identified a 
population of cells that were enriched for infection using the J3 Env nanobody and also contained 
gag-pol, nef, and vif transcripts. These cells were characterized as CD4+ T cells, but deeper 
characterization of the exact subset is still needed. We also observed HIV-1 transcripts in 
macrophages. To validate the transcriptomic data, we ran flow cytometry using cellular markers, 
anti-HIV-1 p24 Gag staining, and J3 anti-Env staining, to verify the infected cell subtypes. We 
found that there were cells in the CD3+, and CD4+ T cell populations and cells in the CD33+, 
CD14+, CD68+, and CD163+ myeloid lineage cell populations.  
Cells of myeloid origin have been previously reported to harbour the HIV-1 reservoir; however, 
the mechanisms of infection and persistence remain controversial. Research has shown that 
macrophages infect CD4+ T cells (Abbas et al., 2015) or conversely that CD4+ T cells  infected 
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macrophages (Groot et al., 2011). Or that macrophages are able to maintain HIV-1 infection 
independently of CD4+ T cells (Honeycutt et al., 2016). Therefore, the finding that the cellular 
HIV-1 reservoir in lymph nodes is partly harboured in cells of myeloid origin is a unique and 
novel find that requires further in-depth studies to understand how this cellular reservoir is formed 
and what the implications in terms of persistence and eradication strategies are.  
Our data showed the cellular HIV-1 reservoir in lymph nodes from ART suppressed individuals 
is harboured in CD4+ T cells and macrophages. The exact CD4+ T cell subtypes still need to be 
defined through further analysis of the transcriptomic data. It is clear that the HIV-1 reservoir is 
not in one cellular compartment as previously suggested (Banga et al., 2016, Descours et al., 
2017). This will make a functional cure more difficult as a variety of cell types will need to be 
targeted in order to reduce or eradicate the HIV-1 reservoir. 
 
Methods 
 
Study participants 
To investigate the HIV-1 LN reservoir, have assembled a cohort of LN from individuals on 
suppressive ART undergoing indicated lung lobe resection or diagnostic procedures in 
collaboration with clinicians at the Department of Cardiothoracic Surgery at Inkosi Albert Luthuli 
Central Hospital in Durban, South Africa. Lymph nodes were obtained from study participants 
undergoing surgery for diagnostic purposes or complications of inflammatory lung disease. 
Informed consent was obtained from each participant. The study protocol was approved by the 
University of KwaZulu-Natal Institutional Review Board (approval BE024/09). We obtained 
matched samples of peripheral blood from each individual. We used peripheral blood to measure 
viral load to determine if the ART regimen was effective at suppressing peripheral viremia below 
the level of detection (<40 HIV-1 copies/ml using Roche AMPLICOR). We also measured the 
concentrations of currently used antiretroviral drugs (ARVs) in South Africa in the peripheral 
blood as well as in cells from the lymph node compartment. Measured ARVs were efavirenz 
(EFV), emtricitabine (FTC) and its triphosphorylated intracellular form, tenofovir (TFV), 
lopinavir and ritonavir (LPV/r), lamivudine (3TC), and nevirapine (NVP). Levels of ARVs were 
an independent measure of the ART regimen and study participant adherence.  
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Primary cells 
Peripheral blood mononuclear cells (PBMCs, from HIV-1 negative donors) were isolated by 
density gradient centrifugation using Histopaque 1077 (Sigma-Aldrich) and cultured at a 
concentration of 106 cells/ml in complete RPMI 1640 medium. The RPMI 1640 medium was 
supplemented with sodium pyruvate, L-Glutamine, HEPES, non-essential amino acids (Lonza), 
10% heat-inactivated FBS (GE Healthcare Bio-Sciences, Pittsburgh, PA) as well as IL-2 at 
5ng/ml (PeproTech, Rocky Hill, NJ). Phytohemagglutinin at 10µg/ml (Sigma-Aldrich) was added 
to activate the cells.  
 
Cells from lymph node samples, isolated from HIV-1 positive and negative study participants, 
were obtained by mechanical separation of the lymph nodes. The cells were frozen at 5 ´ 106 
cells/ml in a solution of 90% FBS, 10% DMSO, and 2.5 µg/ml Amphotericin B (Lonza). Cells 
were stored in liquid nitrogen until use, then thawed and resuspended at 106 cells/ml in RPMI 
1640 medium supplemented with sodium pyruvate, L-Glutamine, HEPES, non-essential amino 
acids (Lonza), 10% heat-inactivated FBS (GE Healthcare Bio-Sciences, Pittsburgh, PA) as well 
as IL-2 at 5ng/ml (PeproTech, Rocky Hill, NJ). 
 
Cell lines 
Rev-CEM cells were obtained from the NIH AIDS Reagent Program. They were cultured in R10 
media (500ml RPMI 1640 supplemented with 5ml L-glutamine, 5ml HEPES, and 50ml FBS). 
We have subcloned the Rev-CEM-E7 clonal line which has >70% GFP expression upon infection 
(Boulle et al., 2016).  
 
Infection 
Lymph node cells and CD4+ T cells from the HIV-1 negative study participants were stimulated 
with anti-CD3 antibody. The plate was prepared the day before. Coating buffer (8.4g NaHCO3, 
3.56g Na2CO3, 1L ddH2O, pH to 9.5, sterile filtered for TC) was made and 2µg/ml (20µl) of anti-
CD3 antibody (Biolegend, Cat # 317315) was added to the coating buffer and vortexed to mix. 
400µl of coating buffer was aliquoted into each well of a sterile, non-TC treated24 well plate 
(Corning, Cat #3473) and sealed. The plate was incubated overnight at 4C°. The plate was washed 
twice with phosphate buffered saline (PBS) and then 400µl of R10/50 added to each well. The 
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lymph node cells were then thawed in 10ml of R10, centrifuged at 300g for 7 minutes and 
resuspended in 1ml of R10. The cells were counted for viability and resuspended at 2 x 106/ml 
with R10/15. 4µg/ml of anti-CD28 antibody (Biolegend, Cat # 302923) was added to the cells 
and then 400µl of cell were added to each well of the 24 well plate and incubated in a 37C° 
incubator. After five days the cells were harvested, counted, centrifuged at 300g for 3 minutes, 
washed with 15ml of R10, and resuspended at 106 in R10/50. The cells were transferred to a 96-
well V bottomed plate and centrifuged at 2400rpm at 4C° for 3 minutes. The cells were washed 
with 200µl of R10 and resuspended in 85µl of R10/50 (R10 media with 1ng/ml IL-2 – 
recombinant IL-2) and transferred to a 96-well flat-bottomed plate. 40µl of the appropriate virus 
(JR-CSF BFP, NL4-3 BFP, or 89.6 BFP) was added to each well. Two wells were left for a mock 
infection per sample. The plates were centrifuged at 800g with an acceleration of 1 for 10 minutes. 
At 9 minutes the temperature was changed to 37C° and the time to 59 minutes. The plate was then 
placed a 37C° incubator for 3 hours. The cells were then transferred to a 96 well V bottomed plate 
and centrifuged at 2400rpm for 3 minutes and then resuspended in 100µl of R10/50 and 
transferred to a round-bottomed plate. The plate was placed in a 37C° incubator for 48 hours. 
Rev-CEMs were infected with 2 x 108 NL4-3 viral copies/ml as previously described (Jackson et 
al., 2018) for a cell-free infection. 
 
Staining and flow cytometry for anti-HIV-1 p24 Gag and anti-Env 10-1074 and J3 
The 10-1074 monoclonal antibody was conjugated to Alexa Fluor 488 (ThermoFisher Scientific) 
and the J3 nanobody was conjugated to Alexa Fluor 647. Cells were stained in phosphate buffered 
saline (PBS) with 10% FBS (GE Healthcare Bio-Sciences, Pittsburgh, PA) and 1mM ETDA with 
1µl of 10-1074 (4mg/ml) and 1µl J3 (50nM). Cells were acquired and sorted on a SH800S Cell 
Sorter and data analyzed using FlowJo 10.0.8 software. 1000 cells per population were sorted into 
a solution of RLT buffer (Qiagen) and 1% b-mercaptoethanol. RNA was extracted using the 
Qiagen RNeasy Plus Micro Kit and converted to cDNA. cDNA synthesis was performed in 20µl 
reactions following the SuperScript IV manufacturer’s instructions (ThermoFisher Scientific) 
with primer 1.3MOD2Malbec (5’ – GTGAGTGATGGTTGAGGTGTGAGTGAGAGCACTCA 
AGGCAAGCTTTATTGAGGC – 3’). Nested PCRs of the HIV-1 reverse transcriptase region 
were performed as described previously (Jackson et al., 2018). The amplified PCR products were 
visualized using gel electrophoresis as well as on a 4200 TapeStation System (Agilent).  
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To determine the number of HIV-1 infected cells from both the in vitro infected PBMCs and in 
vivo infected lymph node cells by anti-HIV-1 p24 staining, cells were then fixed and 
permeabilized using the BD Cytofix/Cytoperm Fixation/Permeabilization kit (BD Biosciences). 
Cells were then stained with anti-p24 FITC or PE conjugated antibody (KC57, Beckman Coulter, 
Brea, CA). Cells were then acquired on a SH800S Cell Sorter (SONY) and data analyzed using 
FlowJo 10.0.8 software. 
 
 
Amplification of full-length HIV-1 genomes from lymph node cells 
RNA was extracted using the Qiagen RNeasy Plus Micro Kit and converted to cDNA. cDNA 
synthesis was performed in 20µl reactions following the SuperScript IV manufacturer’s 
instructions (ThermoFisher Scientific) with primer 1.3MOD2Malbec (5’ – 
GTGAGTGATGGTTGAGGTGTGA GTGAGAGCACTCAAGGCAAGCTTTATTGAGGC – 
3’). DNA was extracted using the Qiagen DNeasy Blood & Tissue Kit. The cDNA product and 
the DNA were then amplified using a nested PCR in 50ul reactions following the Phusion High-
Fidelity DNA Polymerase manufacturer’s instructions (NEB). The HIV-1 genome was amplified 
in two 4.5kb fragments as opposed to one 9kb fragment. The first half genome first round primers 
were as follows: SubC_R_For1 (5’ – GTCTCTCTAGGTAGA CCAG – 3’) and SubC_Int_Rev1 
(5’ – CCTTTCCAAATAGGGTCTC – 3’). The second half genome second round primers were 
as follows: SubC_Int_For1 (5’ – CGGGTTTATTACAGAGAGACAGC – 3’) and 
SubC_R_Rev1 (5’ – TARAGCACTCAAGGCAAGC – 3’). The first half genome second round 
primers were as follows: R_For_2 (5’ – GTCTCTCTAGGTAGACCAGATCTGAGC – 3’) and 
Int_Rev_2 (5’ – GTCTCTGCTGTCTCTGTAATAAACCC – 3’). The second half genome 
second round primers were as follows: Int_For_2 (5’ – 
AGAGACAGCAGAGACCCTATTTGGAAAGG – 3’) and R_Rev_2 (5’ – TARAGCAC 
TCAAGGCAAGCTTTATTGAGG – 3’). Amplified products were visualised using gel 
electrophoresis. The products were gel purified using the Wizard SV Gel and PCR Clean-Up 
System. The samples were then prepped for sequencing using the Nextera XT DNA Library 
Preparation Kit (Illumina) and sequenced on a MiSeq System (Illumina). Sequences and 
phylogenies were assembled using Geneious (v11.0.5). The phylogenetic tree was created using 
the neighbour-joining method with the HKY85 genetic distances model.  
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Staining, magnetic activated cell sorting, and Seq-Well 
Lymph node cells were thawed in 10mls of R10 media and centrifuged at 300g for 7 minutes and 
resuspended in 1ml MACS buffer (phosphate buffered saline, 2% heat-inactivated FBS (GE 
Healthcare Bio-Sciences, Pittsburgh, PA), and 1mM EDTA). Cells were counted and resuspended 
at different concentrations: 40,000 cells in 800ul for unsorted Seq-Well arrays; 500,000 cells for 
CD4 enrichment; 500,000 cells for CD19 depletion; and the remaining cells (>3 x 106) for J3 
enrichment. The CD4 enrichment, CD19 depletion, and J3 enrichment tubes were centrifuged at 
300g for 3 minutes. The cells for CD4 enrichment and CD19 depletion were separately 
resuspended in 80µl MACS buffer and 2.5µl FcR blocking reagent for 10 minutes at 4C° after 
which 20µl of CD4 MACS beads and 20µl CD19 MACS beads (Miltenyi Biotec) were added to 
their respective tubes and kept at 4C° for a further 15 minutes. The cells for J3 enrichment were 
resuspended in 50µl of MACS buffer and 1µl of J3 conjugated to biotin and incubated for 30 
minutes at 4C°. 5ml of MACS buffer was then added to the cells, before they were centrifuged at 
300g for 3 minutes to wash. Cells were resuspended in 90µl of MACS buffer and 10µl of 
streptavidin beads were added and then incubated at 4C° for 15 minutes. 2ml of MACS buffer 
was added to each condition after incubation, and the cells were centrifuged at 300g for 3 minutes 
before being resuspended in 500µl of MACS buffer. LD columns (Miltenyi Biotec) were used for 
the CD19 depletion and CD4 enrichment and LS columns (Miltenyi Biotec) were used for the J3 
enrichment. The columns were prepared with three washes of 3ml MACS buffer. The cells were 
then passed through the columns and the columns washed three times whilst the columns were 
on the MACS Manual Separators magnet (Miltyeni Biotec). The negative fraction was collected. 
The columns were then taken off the magnet and the positively selected cells were plunged into 
a 15ml conical, washed three times, centrifuged at 300g for 3 minutes, and resuspended in 500µl 
of R10. The cells were counted with Trypan Blue (ThermoFisher Scientific) and 15,000 live cells 
from each condition added to each array.  
The Seq-Well protocol was then followed on the arrays (Gierahn et al., 2017) and the samples 
were either sequenced on a NextSeq 550 Series (Illumina) using an Illumina 75 cycle 
NextSeq500/550 v2 kit (Illumina FC-404-2005). 
 
Single-cell RNA-seq of infected Rev-CEM-E7 cells using Smart-Seq2 
Single NL4-3 in vitro infected Rev-CEM cells were sorted into 96-well plates and processed 
through reverse transcription, whole transcriptome amplification (WTA), and library preparation 
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following the previously described protocol (Trombetta et al., 2014). The samples were 
sequenced on a NextSeq 550 Series (Illumina) using 30bp ends. Reads were aligned to the Hg19 
genome and to the NL4-3 genome as previously described (Macosko et al., 2015) using STAR 
(Dobin et al., 2013) and Hisat2 (Kim et al., 2015). Low quality cells were trimmed (cells with 
<25,000 mapped reads or <1000 genes) and differential expression analysis of genes based on 
HIV-1 infection of the cells was conducted in Seurat (Satija et al., 2015). Gene expression based 
on HIV-1 infection was plotted in a heat map showing genes that were found to be expressed in 
HIV-1 infected cells versus genes that were associated with cells not infected with HIV-1. 
 
 
Single-cell RNA-seq alignment and cell type identification from Seq-Well data 
Read alignment was performed as in previously described (Macosko et al., 2015, Ordovas-
Montanes et al., 2018) using the Hg19 genome and the HIV-1 Clade C consensus genome. Cell 
barcode discrimination and UMI/transcript collation were performed as previously described 
(Ordovas-Montanes et al., 2018). The pilot study run on the lymph node cells from PID 024-09-
0198 was analysed separately from the rest of the cohort. Cells with less than 500 UMIs detected 
or more than 5000 UMIs were excluded as well as any gene expressed in less than 5 cells from 
any downstream analysis. Any cell with at least 300 unique cells was retained. This was done on 
all of the arrays that were processed per study participant, on an individual basis. These objects 
were then merged into one object for cell type identification across all study participants, except 
for PID 024-09-0198, which was analysed separately using the same parameters.  
A combined Seurat (version 2.3.4) (Satija et al., 2015) object was created for all the study 
participants except PID 024-09-0198, and log normalized with a size factor of 10,000. The object 
was scaled with centering. A total number of 22,114 cells passed these parameters with 39,385 
unique genes. We then ran principle component analysis (PCA) over this list of variable genes. 
For the t-SNE plots we used the first 36 principal components as indicated by the inflection on 
the elbow plot. We used FindClusters within Seurat (uses shared nearest neighbour (SNN) 
modularity optimization-based clustering algorithm to identify clusters) with a resolution of 2.4 
to identify 31 clusters across the 8 input samples. We also plotted the cells on a t-SNE by study 
participant and by array type, to better understand the distribution of cells.  
For PID 024-09-0198, we merged data from two arrays and found variable genes using 9 principal 
components to create a t-SNE plot. With FindClusters we found 9 clusters. We used the ‘bimod’ 
function in FindMarkers implemented in Seurat which uses a likelihood-ration test for identifying 
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differentially expressed genes in single-cell data. The FeaturesPlot implemented in Seurat, which 
colours cells on a dimensional reduction plot according to ‘feature’, was used to indicate genes 
that were highly expressed in each cluster and were used as markers to identify the cell type of 
each cluster. The normalized expressions of the top 100 genes per cluster were plotted on a 
heatmap. We then merged the datasets that had aligned to HIV-1 into the matrix and plotted the 
same t-SNE and including the total gag-pol transcripts across it. We then created vectors for each 
HIV-1 gene including env, vif, and tat to determine the sensitive range for each gene. Once the 
cut-off had been determined, the same t-SNE was plotted as above with shapes for the cells that 
had HIV-1 transcripts.  
The in vitro infected cells were analysed separately. Four arrays were sequenced per infection: 
unsorted, NL4-3 infected BFP negative, NL4-3 infected BFP positive, and mock infected. A 
violin plot was created in Seurat to show the abundance of HIV-1 UMIs across the four conditions 
and a t-SNE plotted by infection condition. The correlation HIV-1 infection as determined by 
flow cytometry in comparison to HIV-1 transcripts from the Seq-Well data was plotted using 
Prism (version 7.0).  
  
Antibodies 
The following antibodies were used: PE conjugated CD3, APC conjugated CD33, PE-Cy7 
conjugated CD19, BV711 conjugated CD4, APC conjugated CD8, PE conjugated CD14, BV711 
conjugated CD68, PE conjugated CD163. Monoclonal antibodies were purchased from Beckton 
Dickinson; CA, USA). FITC conjugated and PE conjugated anti-HIV-1 p24 Gag (KC57) was 
from Beckman Coulter (CA, USA).  Anti-Env broadly neutralizing antibody 10-1074 was 
obtained from the NIH AIDS Reagents Program and conjugated to Alex Fluor 488 (ThermoFisher 
Scientific). The anti-Env antibody J3 was acquired from Bruce Walker’s laboratory conjugated 
to Alex Fluor 647 or to biotin. 
 
Flow Cytometry and sorting of in vivo infected lymph node cells 
Lymph node cells were thawed in 10mls of R10 media and centrifuged at 300g for 7 minutes and 
resuspended in 1ml MACS buffer (phosphate buffered saline, 2% heat-inactivated FBS (GE 
Healthcare Biosciences, Pittsburgh, PA), and 1mM EDTA). Cells were counted and resuspended 
at 1 x 106 cells/ml before staining. Cells were acquired and sorted on a Sony SH800S Cell Sorter 
and data analyzed using FlowJo 10.0.8 software. 1000 cells were sorted for each population of 
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cells positive for anti-HIV-1 p24 Gag into PKD buffer and RNA was extracted using the RNeasy 
FFPE Kit (Qiagen). The Smart-Seq2 protocol was followed for sequencing and libraries were 
prepared as previously described (Trombetta et al., 2014). 
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CHAPTER 3: DISCUSSION/SYNTHESIS 
 
HIV-1 persistence in the face of ART necessitates lifelong adherence to treatment. Identifying 
the cellular HIV-1 reservoir in ART suppressed individuals is critical to creating a functional 
therapeutic cure. Previous studies have identified different cell subsets including CD32a 
expressing T cells (Descours et al., 2017), PD-1 expressing T cells (Banga et al., 2016, Fromentin 
et al., 2016), follicular T helper cells (Perreau et al., 2013, Vinuesa, 2012), or resting memory T 
cells as harbouring the HIV-1 reservoir (Siliciano and Siliciano, 2015). However, the 
establishment and size of the reservoir could depend on many factors and different cell types 
could be infected in different individuals. For example, CD32a expressing T cells have recently 
been shown to not harbour the HIV-1 reservoir (Badia et al., 2018, Perez et al., 2018). Rather, 
CD32a was postulated to be a marker of T cell activation.  
Persistence results from reservoirs of HIV-1 infected cells at several possible anatomical reservoir 
sites (Fois and Brew, 2015, Horiike et al., 2012, Kulpa and Chomont, 2015, McElrath et al., 2013, 
Svicher et al., 2014). A critical reservoir site is lymphoid tissue, comprising lymph nodes (Horiike 
et al., 2012, Spiegel et al., 1992) and gut associated lymphoid tissue (Marcelin et al., 2008, Politch 
et al., 2012). However, most of the studies investigating the cellular HIV-1 reservoir have been 
done either using in vitro experiments or PBMCs isolated from ART suppressed individuals 
(Chargin et al., 2015, Cohn et al., 2018, Ho et al., 2013). Few studies have been performed in 
lymph nodes from ART suppressed study participants (Denton et al., 2012, Honeycutt et al., 2017, 
Marsden et al., 2012). In addition, there is very little known about the HIV-1 reservoir in southern 
Africa, the geographical area with by far the most HIV-1 infected individuals on ART (Granich 
et al., 2012, Vermund et al., 2015). Here, we aimed to identify the cellular HIV-1 reservoir in 
lymph nodes from ART suppressed participants from South Africa who were infected with Clade 
C viruses, hence investigating the HIV-1 reservoir at the epicentre of the HIV-1 epidemic.  
We established a cohort of participants in collaboration with cardiothoracic clinicians at the Inkosi 
Albert Luthuli Central Hospital in Durban. All of study participants used in this study were 
suppressed on ART and had no detectable peripheral viremia (<40 HIV-1 copies/ml). 
Antiretroviral (ARV) drug levels were quantified in the matched blood samples from each study 
participant using liquid chromatography–tandem mass spectrometry (LC-MS/MS). 
To investigate the HIV-1 infected cell type in the HIV-1 reservoir in the face of ART, we 
developed a novel single-cell RNA sequencing approach, which had not been previously used to 
identify HIV-1 infected cells from lymphoid tissues. We coupled HIV-1 transcript detection to 
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Seq-Well (Gierahn et al., 2017), a high throughput single-cell RNA-Seq methodology developed 
by our collaborating lab at the Massachusetts Institute of Technology and the Ragon Institute of 
MGH, MIT, and Harvard. Seq-Well allows for the transcriptomic profiling of thousands of cells 
in parallel. However, due to the low frequency of HIV-1 infected cells (<1%) we had to identify 
ways to enrich for these cells. A previous study (Cohn et al., 2018) had used biotinylated anti-
Env broadly neutralizing antibodies to enrich for HIV-1 infected cells using magnetic activated 
cell sorting. We employed the same method using the J3 nanobody (McCoy et al., 2012) and ran 
the Seq-Well protocol on the total lymph node cell population and on cells enriched for HIV-1 
Env expression.  
Analysis of our single-cell data indicated that CD4+ T cells and macrophages contained HIV-1 
transcripts. In our pilot study, we identified various T cell subsets including memory T cells and 
cycling T cells as containing HIV-1 transcripts. These cell types have been identified to harbour 
the HIV-1 reservoir in previous studies (Baxter et al., 2014, Siliciano and Siliciano, 2015). 
However, our data shows that the HIV-1 reservoir is not isolated to single cell type or cellular 
marker as suggested by previous studies (Banga et al., 2016, Descours et al., 2017, Noto et al., 
2018). We showed that there is a diversity in cell types which contain HIV-1 transcripts, although 
this does not necessarily mean that the virus is fully functional. 
The use of single-cell RNA sequencing to identify cells which contain HIV-1 transcripts is a novel 
technique in the field of HIV-1 reservoirs. It allows us to identify these cells across all cell types 
found in the lymph node in an unbiased way without having to pre-select cell types which are 
most likely to contain virus or are generally thought to be the HIV-1 reservoir. However, due to 
the low frequency of cells containing transcripts, enrichment was necessary and therefore we used 
enrichment based on HIV-1 expression in parallel to the total cell population.  To investigate if 
cell populations detected by our approach actually produce infection competent virus, quantitative 
viral outgrowth assays would need to be conducted. This a drawback of the methods we have 
used.  
In addition to the development of a novel technique for HIV-1 reservoir detection, we amplified 
whole HIV-1 genome sequences from extracted genomic DNA from the lymph node cells from 
each study participant. We used these genomes in alignments of single-cell RNA-Seq transcripts. 
We found better alignment when the transcriptomic data was aligned to the HIV-1 genome 
sequence from the same study participant compared to the HIV-1 Clade C consensus sequence. 
Furthermore, we ran flow cytometry on lymph node cells to identify populations that were anti-
HIV-1 p24 Gag positive. We bulk sorted the p24 positive populations and ran population RNA 
sequencing on these cells after decrosslinking the RNA. We are currently comparing the gene 
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signatures from these cells with those from the single-cell data to further validate our 
transcriptomic data (data not shown in this thesis). 
A further application of single-cell RNA sequencing to this project would be to sort single cells 
into 96-well plates and sequence the HIV-1 virus in these cells to determine clonality. This is 
important since latency would predict clonal sequences whilst ongoing replication would predict 
sequences that diverge. Therefore, it is possible to use this technique to investigate the 
mechanisms of HIV-1 persistence in the context of the HIV-1 reservoir and whether this 
mechanism is latency or not. We have already begun doing so by sorting single cells positive for 
anti-Env broadly neutralizing antibodies 10-1074 and J3 from each HIV-1 infected study 
participant. However, we are still running downstream experimental components and therefore 
the data is not shown in this thesis. 
In conclusion, our data shows that there is diversity in the cell types that harbour HIV-1 transcripts 
in the lymph node cells from ART suppressed individuals. CD4+ T cells and macrophages make 
up the majority of cells that contain these transcripts, with different subsets of T cells containing 
transcripts including memory T cells and circulating T cells. This goes against the hypothesis that 
the HIV-1 reservoir is restricted to a particular cellular subset or can be identified with a singular 
cell marker. However, further data analysis of our data is required to determine exactly which T 
cell subsets are infected and the diversity of these subsets across all study participants is, as the 
above results are based on preliminary analysis. The cells which are infected have poor quality 
RNA due to being infected with HIV-1 and even with sufficient sequencing depth, it is difficult 
to correctly identify them as belonging to a specific cell subset.  
This study used novel techniques and methods to identify HIV-1 infected cells in the lymph node 
compartment and these can be further optimized to be used on different reservoir sites as well as 
to better identify the infected cells. The next steps of this project, along with further data analysis, 
are to further optimize the pull-down of HIV-1 transcripts from the mRNA captured on the Seq-
Well beads as well as and to complete the flow cytometry validation for all study participants.  
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